|
Rheumatoid Arthritis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, our study demonstrates a functional effect of <i>IL12B</i> polymorphisms on IL-12p40 and IL-23 cytokine levels in RA patients and suggests a leading role for <i>IL12B</i> rs17860508 in the genetic predisposition to RA, while <i>IL12B</i> rs3212227 significantly modify the RA risk in Bulgarian population.
|
31161840 |
2020 |
|
Rheumatoid Arthritis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The IL-17 and IL-23 levels were not different between AS and RA (p = 0.409 and p = 0.562, respectively).
|
31830775 |
2020 |
|
Rheumatoid Arthritis
|
0.400 |
Biomarker
|
disease |
BEFREE |
In early RA, the involvement of anticitrullinated protein antibodies in RA induction has been identified with a critical role of the IL-23/Th17 axis in the control of their pathogenicity.
|
31644463 |
2020 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this systematic review, we examined the time to onset of action for interleukin (IL)-17 and IL-23 agents in the treatment of psoriasis.
|
31465593 |
2020 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
IL-17C was depleted using a new IL-17C specific antibody (MOR106) in murine models of psoriasis (IL-23 injection model) and AE (MC903 model) as well as in human skin biopsies of psoriasis and AE.
|
31793105 |
2020 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
As in anti-IL-17 or anti-IL-23 antibody treatment, the dual action of phototherapy on skin and the immune system is likely responsible for sustained resolution of lesions in diseases such as psoriasis.
|
31753191 |
2020 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Ustekinumab, an antibody to p40, blocks cytokines IL-12 and IL-23, and is a highly effective and safe treatment for psoriasis.
|
31326395 |
2020 |
|
Psoriasis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The inflammatory process and immunostaining of IL-6, IL-17, and IL-23 were similar in geographic tongue and psoriasis, suggesting the existence of a type of geographic tongue that represents an oral manifestation of psoriasis.
|
31789253 |
2020 |
|
Rheumatoid Arthritis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Cytokines of the Interleukin (IL)-12 family, consisting of IL-12, IL-23, IL-27 and IL-35, are important regulators in (chronic) inflammatory disorders such as rheumatoid arthritis and multiple sclerosis, but also in cardiovascular diseases.
|
29074035 |
2019 |
|
Rheumatoid Arthritis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
These lymphoid structures are associated with activation of the IL-23/Th17 pathway in RA and seemly in PsA, which could be useful to stratify RA patients.
|
30805340 |
2019 |
|
Rheumatoid Arthritis
|
0.400 |
Biomarker
|
disease |
BEFREE |
The present review discusses the different aspects of IL-23 including its structural features, signal transduction pathway, preclinical, and clinical role in RA.
|
31072166 |
2019 |
|
Rheumatoid Arthritis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Besides Th17- and Treg-associated cytokines, elevated expression of IL-27/IL-23 cytokines might also be responsible for increased disease severity in female patients with RA.
|
31177017 |
2019 |
|
Rheumatoid Arthritis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Moreover, interleukin-23 (IL-23), and IL-17 are vital to the pathogenesis of RA.
|
30856393 |
2019 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Activation of the IL-23/IL-17 pathway is integral to the development of psoriasis.
|
30926837 |
2019 |
|
Psoriasis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Conversely, reducing mtROS production or DC-specific deficiency in XBP1 attenuated IL-23 expression and skin inflammation in an IL-23-dependent model of psoriasis.
|
31031005 |
2019 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Tildrakizumab (tildrakizumab-asmn in the USA) [Ilumetri<sup>®</sup>; Ilumya™] is a humanized monoclonal antibody (mAb) that selectively targets the p19 subunit of interleukin (IL)-23, thereby inhibiting the IL-23/IL-17 axis, the signalling pathway primarily implicated in the immunopathogenesis of psoriasis.
|
30924030 |
2019 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Currently, there is no cure for PsO; however, the introduction of biologic therapies has revolutionized the clinical management of patients with PsO by expanding treatment options to include multiple therapies with different mechanisms of action targeting cytokines, including tumor necrosis factor inhibitors (TNFis), interleukin (IL)-17A inhibitors, an IL-12/23 inhibitor, and IL-23 inhibitors.
|
31424708 |
2019 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Disrupting the IL-36 and IL-23/IL-17 loop underlies the efficacy of calcipotriol and corticosteroid therapy for psoriasis.
|
30674716 |
2019 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Interleukin (IL)-23 is considered an effective therapeutic target for the treatment of psoriasis because of the crucial role of the IL-23/IL-17 axis in the pathogenesis of psoriasis, and it has recently been reported to be involved in ILC3 cell differentiation.
|
31454926 |
2019 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our study suggests that Stat3 activation in keratinocytes may impact on LC activation in situ via IL-1α stimulation, at least in part, and that their presence may be essential for the pathogenesis of psoriasis through producing IL-23.
|
30514663 |
2019 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Anti-IL-23p19 mAbs are effective with acceptable safety as therapy for psoriasis, and may be superior to TNF antagonists.
|
31389789 |
2019 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Within 12 weeks of treatment, interleukin-12 (IL-12)/IL-23 inhibition for psoriasis appears to suppress subclinical enthesopathy, and the suppression is maintained through week 52.
|
30468001 |
2019 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
On the other hand, inhibition of IL-12-IL-23, as compared with inhibition of TNF, has greater efficacy for psoriasis, comparable efficacy for peripheral arthritis, but was ineffective in studies of axial spondyloarthritis.
|
31485004 |
2019 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
IL-23 is also implicated in the pathogenesis of Crohn's disease (CD) and psoriasis, both of which can occur in patients with HS.
|
31389737 |
2019 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Biologic treatment options for psoriasis will continue to grow, especially IL-17 and IL-23 related agents, with an increasing specificity of agents to be available in the future.
|
30500317 |
2019 |